Latigo Biotherapeutics Files for Nasdaq IPO, Targeting Up to $288 Million

Latigo Biotherapeutics, Inc. has filed for an initial public offering on the Nasdaq, aiming to raise up to $288 million in new capital. The company plans to list its common stock on the Nasdaq Global Select Market under the proposed ticker symbol "LTGO."

Offering Details

According to the company's regulatory filing, Latigo Biotherapeutics intends to offer 16,000,000 shares of its common stock. The anticipated price for the IPO is expected to be between $16.00 and $18.00 per share.

This offering will mark the company's debut on the public markets. Prior to this planned IPO, there has been no public market for Latigo Biotherapeutics' common stock.

Ad

Financial Implications

At the maximum price of $18.00 per share, the offering would generate gross proceeds of $288 million for the company, before deducting underwriting discounts and other expenses. An IPO is a standard path for a private company to raise significant capital to fund operations, research, and expansion.

The successful completion of the offering will depend on investor demand and broader market conditions. The final price will be determined following the company's roadshow with potential institutional investors.